Accuracy of transbronchial needle aspiration for mediastinal staging of non-small cell lung cancer: a meta-analysis

Jon-Erik C. Holty, M.D.
Ware G. Kuschner, M.D.
Michael K. Gould, M.D., M.S.

Online data supplement
METHODS

We used systematic methods to identify relevant studies, apply inclusion and exclusion criteria, evaluate study quality and summarize the diagnostic accuracy of TBNA for mediastinal lymph node involvement in patients with non-small cell lung cancer.

Literature search

An investigator (J.C.H.) and a professional librarian developed a computerized search strategy to identify relevant studies published between January 1966 and 1 July 2003 in the Medline and Embase electronic databases. This strategy employed key words (both controlled vocabulary and free text terms) and was divided into three parts each connected by the [AND] bullion. The first part mapped the search to non-small cell lung cancer and included key words such as lung neoplasm/cancer, bronchial neoplasm/cancer or carcinoma/cancer non-small-cell lung. The second part of the search strategy mapped the search to staging concepts and included key words such as neoplasm staging, lymphatic/lymph-node metastasis, neoplasm metastasis or mediastinal cancer/neoplasm. The final part mapped the search to TBNA and included key words such as bronchoscopy/transbronchial/TBNA and biopsy/needle biopsy/aspirate/sentinel lymph node biopsy/FNA. We first searched for articles in the Medline database. All duplicate articles found in the Embase database were excluded as well as non-human studies. A detailed description of our initial search strategies is shown in fig S1A and B.

We updated the literature search in Medline through 6 April 2004 by employing the key words (both controlled vocabulary and free text terms) transbronchial or TBNA. In addition, we manually searched reference lists of included studies and review articles and reviewed practice
guidelines and systematic reviews. All articles regardless of language were considered for inclusion.

**Inclusion and exclusion criteria**

The initial search strategy (fig S1A and B) yielded a total of 525 articles (fig 1). A careful review of titles and abstracts eliminated 398 articles not dealing with TBNA. A hand search of the bibliographies of the remaining 127 articles identified 203 additional potentially relevant studies. We excluded studies that examined rigid bronchoscopy. An initial review of full reports by one investigator (J.E.H.) excluded 268 studies for the following reasons: not a study of staging (n=106); study of rigid bronchoscopy (n=69); review article or no primary data presented (n=61); or miscellaneous reasons (n=32). Sixty-two potentially eligible studies underwent further review (table S1).

Each non-excluded English-language study was reviewed by at least two investigators (J.C.H., M.K.G. or W.G.K.) to assess whether they met inclusion criteria. To be included, a study had to (1) examine TBNA using a flexible bronchoscope for mediastinal staging in patients with known or suspected NSCLC; (2) enroll at least 10 subjects with and/or 10 subjects without mediastinal lymph node involvement; (3) provide sufficient original data to permit calculation of sensitivity and/or specificity; and (4) for studies that did not provide separate data for participants with disorders other than NSCLC, include no more than ten percent (≤10%) of subjects with primary diagnoses other than NSCLC. This final inclusion criteria was chosen because TBNA may be more sensitive in patients with small cell lung cancer,[1] and because staging and treatment differs between NSCLC and small cell lung cancer.[2][3] These criteria were designed to identify studies that met minimal standards of acceptability.
# Table S1. Potentially eligible studies*

<table>
<thead>
<tr>
<th>Exclusion and inclusion criteria</th>
<th>Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full-text reports for detailed evaluation (n=62)</td>
<td>[4][5][6][7][8][9][10][11][12]</td>
</tr>
<tr>
<td>Study did not examine TBNA using a flexible bronchoscope for mediastinal staging in patients with NSCLC</td>
<td>[4][6][7][8][9][10]</td>
</tr>
<tr>
<td>Fewer than 10 subjects with or without mediastinal metastasis</td>
<td>[13][14][15][16][17][18][19][20][21][22][23]</td>
</tr>
<tr>
<td>Insufficient data to calculate sensitivity or specificity</td>
<td>[5][6][7][8][9][10][11][12][13][14][15][17][18][19][20][21][22][23]</td>
</tr>
<tr>
<td>Fewer than 90% of enrolled subjects had NSCLC or did not provide separate data for patients with NSCLC</td>
<td>[2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23]</td>
</tr>
<tr>
<td>Abstract</td>
<td>[56]</td>
</tr>
<tr>
<td>Met inclusion criteria</td>
<td>[57][58][59][60][61][62][63][64]</td>
</tr>
<tr>
<td>Authors provided additional information that enabled us to include their studies</td>
<td>[1][50][51][54][55]</td>
</tr>
<tr>
<td>Updated Medline search (n=9)</td>
<td>[65][66][67][68]</td>
</tr>
<tr>
<td>Study did not examine TBNA using a flexible bronchoscope for mediastinal staging in patients with NSCLC</td>
<td>[65][66][67][68][69][70]</td>
</tr>
<tr>
<td>Insufficient data to calculate sensitivity or specificity</td>
<td>[65][66][67][68][69][70]</td>
</tr>
<tr>
<td>Fewer than 90% of enrolled subjects had NSCLC or did not provide separate data for patients with NSCLC</td>
<td>[65][71]</td>
</tr>
<tr>
<td>No primary data (e.g. review article)</td>
<td>[72][73]</td>
</tr>
</tbody>
</table>

* Studies could meet one or more exclusion criteria.
Because many studies did not require pathologic confirmation of positive TBNA results, and because this may result in biased estimates of test performance, we divided studies \textit{a priori} into two tiers. Tier 1 studies enrolled at least 10 subjects with and without mediastinal lymph node involvement, surgically confirmed all TBNA results and used the patient as the unit of analysis. Non-tier 1 studies did not meet one or more of these criteria, but met all other criteria for inclusion.

We included abstracts only when the study authors provided full reports of their methods and results. We requested additional information from the authors of all studies that did not report data sufficient to calculate sensitivity and/or specificity for NSCLC staging. If two or more publications by the same authors with overlapping patients were identified, only the most recent study was included. Disagreements were resolved by discussion and/or by consulting with a third investigator (J.C.H., M.K.G. or W.G.K.). A single reviewer evaluated non-English-language studies. A Cohen’s kappa for interrater reliability was calculated to assess agreement about study eligibility between raters (table S2). Based on our selection criteria, we excluded 54 studies that either provided insufficient data to calculate sensitivity or specificity (76%) or enrolled <90% of subjects having NSCLC (60%). We obtained additional unpublished data from seven authors that enabled us to include five additional studies.

\textbf{Table S2}. Cohen’s kappa measure of agreement between reviewers on included studies

<table>
<thead>
<tr>
<th>Reviewer 1 (J.E.H.)</th>
<th>Reviewer 2 (M.K.G.)</th>
<th>Reviewer 3 (W.G.K.)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.83</td>
<td>0.77</td>
</tr>
</tbody>
</table>

5
Study quality

We adapted criteria for methodological quality proposed by Kent et al.,[75] to identify high-quality studies of TBNA for lung cancer staging (fig S2). The revised criteria cover seven assessment categories: technical quality of TBNA, technical quality of the reference test, application of the reference test, independence of interpretations, clinical description, cohort assembly and sample size. These criteria have been used to evaluate several different diagnostic modalities, including CT for lumbar stenosis,[75] polymerase chain reaction for the diagnosis of human immunodeficiency virus infection,[76] and positron emission tomography for the evaluation of focal pulmonary lesions[77] and in the staging of lung cancer.[78] Independent criteria for the technical quality TBNA were developed based on the clinical experience of two of the authors experienced in the use of TBNA (M.K.G and W.G.K) and by reviewing published guidelines.[79][80][81] All English-language studies were assessed by at least two investigators (J.C.H., M.K.G. or W.G.K.) for methodological quality with all disagreements resolved by discussion. One reviewer assessed the quality of all non-English language studies.

Data abstraction

One investigator (J.C.H) abstracted primary data regarding patient characteristics and the sensitivity and/or specificity of TBNA for identifying mediastinal metastasis in patients with NSCLC. To assess the accuracy of TBNA, data abstraction was performed for patients with a primary diagnosis of NSCLC that was confirmed histologically.

When possible, we separated staging characteristics of TBNA for patients with and without enlarged lymph nodes on CT, and for biopsies performed at hilar, subcarinal, paratracheal or other lymph node stations. We also separately tabulated test characteristics for
studies utilizing ‘real-time’ imaging (e.g. CT fluoroscopy, enbronchial ultrasound or transthoracic ultrasound).

**Data synthesis and sensitivity/specificity calculations:**

We constructed 2 x 2 contingency tables for each study to summarize the results of TBNA and the reference test(s). For each study, the true positive rate (TPR; sensitivity), the false-positive rate (FPR; 1-specificity), the log odds ratio (LOR; log odds TPR - log odds FPR) and the kappa-1 statistic were calculated. To calculate log odds ratios, we added a correction factor of 0.5 to each cell in any 2 x 2 table that contained one or more zero values.

Because many studies did not confirm positive TBNA results surgically, the false-positive rates for these studies are unknown. We calculated a weighted kappa-1 coefficient (a generalization of the unweighted or Cohen’s kappa coefficient) to assess accuracy with regards to avoiding false negative results.[82][83] Calculation of the kappa-1 coefficient does not require the false positive rate (1-specificity) (but does require knowledge of the marginal probabilities) thus providing a less biased method to compare diagnostic accuracy in studies that did and did not surgically confirm all positive test results. We calculated a pooled kappa-1 coefficient by using both fixed[84] and random effects models.[85] The asymptotic variance of the weighted kappa coefficient can be estimated.[86] Weighted kappa coefficient values close to one suggest good test accuracy, while values less than 0.40 suggest only fair to poor test accuracy.[83][87]

Summary receiver operating characteristic (SROC) curves as described by Moses et al.,[88][89] were constructed to quantitatively summarize the results of studies. These curves demonstrate the trade-off between sensitivity and specificity as the threshold for defining a positive test varies. This method assumes that individual study estimates of sensitivity and
specificity represent unique points on a common SROC curve. We performed ordinary least squares regression by using the log odds ratio as the dependent variable and an implied function of the test threshold (logit TPR + logit FPR) as the independent variable, and plotted the relationship between the TPR and FPR after performing a reverse transformation, as we have done previously.[77][78] Any studies that enrolled no patients with or without mediastinal lymph node involvement were excluded from the SROC analysis.

When the SROC curve is symmetrical (e.g. $\beta \approx 0$), the studies may be summarized by a common LOR. Beta coefficients were not statistically significantly different from zero for tier 1 studies (0.26; 95% CI, -1.75 to 2.28), non-tier 1 studies (-0.28; 95% CI, -1.34 to 0.79) and all studies combined (0.29; 95% CI, -0.13 to 0.70). The LOR represents the odds of a positive test in subjects with disease relative to the odds of a positive test in subjects without disease. To estimate the common log OR, we employed both fixed[84] and random effects models,[84][85] adding 0.5 to each cell in any 2 x 2 table that contained one or more zero values.

Pooled sensitivity and specificity were calculated by fixed and random effects models. When pooling sensitivity and specificity, studies with <10 subjects with or without mediastinal lymph node involvement were excluded, respectively, in the calculations. Heterogeneity was assessed by the Q-statistic. When there was statistically significant heterogeneity, a random effects model, as described by DerSimonian and Laird,[85] was used to summarize trial results.

Studies often have different thresholds to define positive and negative test results. Thus TPR and FPR are typically positively correlated and therefore not independent. Pooling sensitivity and specificity is often inappropriate.[90][91] However, we believe that separate pooling of the sensitivity and specificity for studies of TBNA for mediastinal staging is appropriate for several reasons. Unlike most other diagnostic tests, the TPR and FPR of TBNA
do not appear to be correlated. Implicit and explicit thresholds are unlikely to affect sensitivity differently from specificity (e.g. TBNA technical criteria that decrease false negative results are unlikely to result in more false positives). In fact, linear regression analysis of tier 1 studies demonstrated a weak (slope near zero), but negative correlation between TPR and FPR. Furthermore, TBNA test results have a dichotomous rather than continuous outcome. Only one false positive was reclassified as a true negative when more stringent reference standards were employed in studies with suboptimal reference standards.

**Sensitivity analysis**

We performed sensitivity analysis to evaluate potential sources of heterogeneity between studies. Sensitivity analysis included stepwise single study elimination to assess significant changes in the LOR or pooled sensitivity. We also assessed whether varying the correction factor from 0.5 to 0.1 had any significant impact on LOR or sensitivity at median specificity on the SROC curve. Finally, we varied assumptions about the definition of a positive or negative biopsy result in certain studies. For example, we reexamined the individual study test results and considered any biopsy specimen negative (when possible) if the biopsy was aborted, if nodal tissue was not located, if there was insufficient tissue for pathologic examination (e.g. inadequate or inconclusive specimens), if the cytopathologist identified the specimen as “contaminated” or if the specimen contained “atypical” cells. All biopsy results that were “suspicious” for malignancy were considered positive as long as the aspirate did not contain an abundance of columnar epithelial cells, if scarce malignant cells were identified or if lymphocytes were absent. We then reanalyzed the pooled sensitivity, specificity, LOR and kappa-1 coefficient based on
these changes and compared this to our base-case analysis (the sensitivity and specificity reported by the study authors).

To date, empirical studies of statistical methods (i.e. funnel plots) in assessing publication bias have focused on randomized clinical control trials of treatment effect and not on diagnostic studies. Thus, there are no universally accepted methods to assess publication bias in trials of diagnostic accuracy. In the absence of any generally accepted method, we constructed inverted funnel plots of standard error versus estimated effect size (LOR) for each individual study to assess for the presence of publication bias.[84] If additional small studies were conducted, but not published due to unfavorable results (e.g. low sensitivity), the funnel plot should be asymmetric.

We also assessed differences in diagnostic accuracy between tier 1 and non-tier 1 studies via discriminant function analysis.[92] This analysis was repeated with respect to studies that confirmed or did not confirm all TBNA results, and studies with high (≥60%) versus low (<60%) prevalence of mediastinal metastasis. P-values were calculated via a parametric Wilks’ Lambda test.

**Meta-regressions**

We performed a multivariate analysis of variance (ANOVA) to examine the effect of specific study characteristics on sensitivity and overall diagnostic accuracy (LOR).[93][94] Study characteristics included prevalence of lymph node metastasis (≥60% or <60%) and year of study publication (≥1995 or <1995).
Statistical models

All biostatistical models were programmed in Excel 8.0 for Windows (Microsoft Corporation, Redmond, Washington, USA). Discriminant function analysis was performed in SAS 9.0 for Windows (SAS Corp, Cary, North Carolina). We calculated 95% confidence intervals (CI’s) for the TPR and the FPR by using the quadratic method.[95] A normal approximation to the binomial of the standard error was used in calculating all other CI’s, as appropriate. When making comparisons between groups of studies we used an unpaired t-test or the Mann-Whitney U test as appropriate. A two-tailed p-value <0.05 was considered statistically significant.
<table>
<thead>
<tr>
<th>Study</th>
<th>Fiberoptic bronchoscope type</th>
<th>Needle type &amp; size</th>
<th>Number of passes*</th>
<th>Real-time imaging</th>
<th>Surgical reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tier 1 studies†</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harrow et al.</td>
<td>N/S</td>
<td>SW-121, SW-122 or MW-319, needle, 21 or 22-gauge (cytology) or 19-gauge (histology)</td>
<td>2 to 3 aspirates</td>
<td>No</td>
<td>Mediastinoscopy, mediastinotomy, or standard or video-assisted thoracotomy</td>
</tr>
<tr>
<td>Bilacergou et al.</td>
<td>Olympus</td>
<td>10-mm long SW-221 needles, 21-gauge</td>
<td>3 to 5</td>
<td>No†</td>
<td>Mediastinoscopy, mediastinotomy or thoracotomy</td>
</tr>
<tr>
<td>Disdier et al.</td>
<td>Olympus (1T20D or P20D) or Pentax 2000E</td>
<td>13-mm long Olympus NA2C needles, 21-gauge</td>
<td>1 to 3 punctures</td>
<td>No</td>
<td>Mediastinoscopy, mediastinotomy or thoracotomy</td>
</tr>
<tr>
<td>Ratto et al.</td>
<td>N/S</td>
<td>Olympus NM-1K 21-Gauge</td>
<td>N/S</td>
<td>No</td>
<td>Mediastinoscopy or thoracotomy</td>
</tr>
<tr>
<td>Schenk et al.</td>
<td>Olympus BF-4B2</td>
<td>Wang aspiration fixed Type 1 or retractable Type 2 biopsy needles</td>
<td>3 to 5 aspirates</td>
<td>No</td>
<td>Cervical or parasternal mediastinal exploration or thoracotomy</td>
</tr>
<tr>
<td>Studies not meeting tier 1 criteria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Herth et al.</td>
<td>N/S</td>
<td>MW-522 needles, 22-gauge</td>
<td>N/S</td>
<td>Endobronchial ultrasound</td>
<td>Thoracotomy</td>
</tr>
<tr>
<td>Wang R. et al.</td>
<td>N/S</td>
<td>Needle 1.85 mm</td>
<td>N/S</td>
<td>No</td>
<td>Thoracotomy</td>
</tr>
<tr>
<td>Patelli et al.</td>
<td>N/S</td>
<td>22-gauge cytology or 19-gauge histology needles</td>
<td>N/S</td>
<td>No</td>
<td>Mediastinoscopy or video-assisted thoracotomy</td>
</tr>
<tr>
<td>Katis et al.</td>
<td>N/S</td>
<td>1.3-cm Olympus NA-1C 21-gauge or 1.5-cm MW-220-1 20 gauge needles</td>
<td>2 to 3</td>
<td>No</td>
<td>Mediastinoscopy or mediastinotomy</td>
</tr>
<tr>
<td>Rong et al.</td>
<td>Olympus BF-1T20</td>
<td>N/S</td>
<td>3</td>
<td>Real-time CT</td>
<td>Thoracotomy</td>
</tr>
<tr>
<td>Schenk et al.</td>
<td>N/S</td>
<td>Wang 22-gauge cytology needle and Wang 19-gauge histology needle</td>
<td>3 to 4 aspirates</td>
<td>No</td>
<td>Mediastinoscopy, mediastinotomy, thoracotomy or percutaneous needle aspiration</td>
</tr>
<tr>
<td>Schenk et al.</td>
<td>Olympus (BF4B2 or P-10)</td>
<td>Wang 18-gauge</td>
<td>3 to 4 aspirates</td>
<td>No</td>
<td>“Surgical mediastinal exploration”</td>
</tr>
<tr>
<td>Wang K. P. et al.</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>No</td>
<td>Mediastinoscopy or thoracotomy</td>
</tr>
</tbody>
</table>
* Number of passes per lymph node station.

† In this study fluoroscopy was occasional used to guide needle placement.

‡ Studies meeting tier 1 criteria surgically confirmed all TBNA’s, had at least 10 subjects with and without mediastinal lymph node metastasis and used the patient as the unit of analysis.

§ Abbreviations: N/S= not specified.
<table>
<thead>
<tr>
<th>Study</th>
<th>Index test technical quality (by test)</th>
<th>Reference test quality (by study)</th>
<th>Application of reference test (by study)</th>
<th>Independence of test interpretation</th>
<th>Clinical description &amp; characteristics</th>
<th>Cohort assembly</th>
<th>Sample size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harrow 2000</td>
<td>8</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Disdier 1998</td>
<td>9</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>4</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Bilacerglu 1998</td>
<td>7</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>4</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>Ratto 1988</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Schenk 1986</td>
<td>7</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td>Patelli 2002</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Herth 2002†</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Wang R. 2002</td>
<td>8</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Katis 1998</td>
<td>7</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>4</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>Rong 1998†</td>
<td>6</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Schenk 1993</td>
<td>10</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>Schenk 1989</td>
<td>7</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Wang K. P. 1983</td>
<td>4</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td><strong>Total number of criteria</strong></td>
<td><strong>13</strong></td>
<td><strong>2</strong></td>
<td><strong>2</strong></td>
<td><strong>3</strong></td>
<td><strong>4</strong></td>
<td><strong>8</strong></td>
<td><strong>2</strong></td>
</tr>
</tbody>
</table>

* Highest possible score is 34.

† Studies that utilized ‘real-time’ imaging to guide needle placement had three additional criteria.
Table S5. Sensitivity analysis: effect of excluding individual studies

<table>
<thead>
<tr>
<th>Studies</th>
<th>Pooled LOR (95% CI)</th>
<th>Pooled sensitivity (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tier 1 studies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harrow et al. 2000</td>
<td>16.8 (5.4 to 52.7)</td>
<td>41% (13% to 68%)</td>
</tr>
<tr>
<td>Bilaceroglu et al. 1998</td>
<td>13.9 (4.8 to 40.7)</td>
<td>29% (18% to 40%)</td>
</tr>
<tr>
<td>Disdier et al. 1998</td>
<td>22.6 (7.4 to 69.3)</td>
<td>40% (13% to 66%)</td>
</tr>
<tr>
<td>Ratto et al. 1988</td>
<td>14.0 (4.5 to 43.9)</td>
<td>45% (24% to 67%)</td>
</tr>
<tr>
<td>Schenk et al. 1986</td>
<td>19.6 (5.6 to 69.6)</td>
<td>39% (12% to 67%)</td>
</tr>
<tr>
<td><strong>Tier 1 summary</strong>*</td>
<td>18.0 (6.6 to 49.2)</td>
<td>39% (17% to 61%)</td>
</tr>
<tr>
<td><strong>Non-tier 1 studies†</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wang R. et al. 2002</td>
<td>55.9 (14.5 to 215.9)</td>
<td>79% (67% to 91%)</td>
</tr>
<tr>
<td>Patelli et al. 2002</td>
<td>51.2 (11.0 to 238.2)</td>
<td>84% (71% to 97%)</td>
</tr>
<tr>
<td>Katis et al. 1998</td>
<td>73.6 (16.5 to 329.1)</td>
<td>81% (69% to 92%)</td>
</tr>
<tr>
<td>Schenk et al. 1993</td>
<td>48.7 (10.7 to 221.9)</td>
<td>80% (67% to 92%)</td>
</tr>
<tr>
<td>Schenk et al. 1989</td>
<td>61.3 (13.7 to 273.4)</td>
<td>80% (69% to 92%)</td>
</tr>
<tr>
<td>Wang K. P. et al. 1983</td>
<td>48.1 (10.7 to 216.7)</td>
<td>80% (67% to 94%)</td>
</tr>
<tr>
<td><strong>Non-tier 1 summary†</strong></td>
<td>52.1 (14.2 to 193.4)</td>
<td>78% (71% to 84%)</td>
</tr>
</tbody>
</table>

* These are the pooled overall results without study elimination.

† The two non-tier 1 studies that utilized ‘real-time’ radiological needle guidance were excluded.[50][51]
References


24


FIGURE LEGENDS

Figure S1A. TBNA Medline search strategy.

Figure S1B. TBNA Embase search strategy.

Figure S2. Methodological quality questionnaire.

Figure S3. Individual study estimates of sensitivity and 1-specificity of TBNA for identifying mediastinal metastasis. Error bars represent 95% CI’s. Point estimates and 95% CI’s for studies with high mediastinal metastasis prevalence (≥60%) and low prevalence (<60%) are shown.

* Specificity was not calculated for the study by Wang, R. et. al.,[85] because the prevalence of mediastinal lymph node metastasis was 100%.

† Specificity is not shown for studies that did not surgically confirm all TBNA results.

‡ Summary high prevalence specificity not shown because only three studies [50][51] allowed calculation of specificity (all 100%), and two of these studies had less than 10 patients without mediastinal metastases.[50][51]

Figure S4. Inverted funnel plot. Log odds ratio (LOR) versus standard error.
| NOT (animal! NOT human/de) |
Figure S1B.

<table>
<thead>
<tr>
<th>Search Term</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>lung neoplasms! OR lung cancer! OR bronchial neoplasms/de OR bronchus cancer! OR</td>
<td>canceroma, non-small-cell lung/de OR lung non small cell cancer/de OR carcinoma!</td>
</tr>
<tr>
<td>Neoplasms, squamous cell! OR (carcinoma, squamous cell! AND lung!) OR</td>
<td>squamous cell carcinoma/de</td>
</tr>
<tr>
<td>(Mediastinum! and neoplasms!) OR mediastinal neoplasms/de OR (mediastinum! AND</td>
<td>neoplasm!) OR mediastinum cancer!</td>
</tr>
<tr>
<td>lung(W)cancer?/ti,ab OR non(W)small(W)cell/ti,ab OR pulmonary(N)neoplasm?/ti,ab OR</td>
<td>pulmonary(N)malignant?/ti,ab OR lung(N)neoplasm?/ti,ab OR lung(N)malignan?/ti,ab</td>
</tr>
<tr>
<td>Neoplasm staging/de OR cancer staging/de OR lymphatic metastasis/de OR lymph node</td>
<td>metastasis/de OR lymph nodes! OR lymph node! OR lymphatic diseases! OR lymphatic system</td>
</tr>
<tr>
<td>OR Stag????/ti,ab OR lymph(W)node/ti,ab OR lymphatic/ti,ab</td>
<td>disease!</td>
</tr>
<tr>
<td>Bronchscopy/de OR bronchoscope?/ti,ab OR transbronchial/ti,ab OR tbna/ti,ab</td>
<td>AND</td>
</tr>
<tr>
<td>Biopsy, needle/de OR needle biopsy/de OR biopsy! OR sentinel lymph node biopsy/de OR</td>
<td>(fine(W)needle?/ti,ab OR aspirat?/ti,ab OR biops?/ti,ab OR tbna/ti,ab)</td>
</tr>
<tr>
<td>NOT (animal! Not human/de)</td>
<td>AND</td>
</tr>
</tbody>
</table>
A. **Index test technical quality (by test)**

1. Was the TBNA technique described in sufficient detail to reproduce the procedure? (Reference to earlier published work that includes a complete technical description is allowable.)

2. Was the type and size of needle used to perform the TBNA noted?

3. Were the following procedure(s) in place to avoid contamination:
   - Was TBNA performed prior to: (1) all brushings, washings and endobronchial biopsies AND (2) inspection of distal airways?
   - Was a separate needle used for each biopsy/aspirate?
   - Was suctioning avoided to prevent aspiration of contaminated respiratory secretions (e.g. was the bronchoscope introduced into the endobronchial tree without suctioning and was suction released prior to withdrawal of the needle)?
   - Were aspirates containing an abundance of columnar epithelial cells, few abnormal cells (e.g. scarce malignant cells) and few lymphocytes considered 'negative' aspirates?

4. Were physician(s) performing TBNA experienced in the procedure as noted by:
   - Were all TBNA’s performed by or under the direct supervision by a trained attending physician?

5. Was computed tomography (CT) assessment of mediastinal lymphadenopathy appropriate as noted by:
   - Were significant mediastinal lymph nodes defined as >1 cm in the short axis diameter?
   - Was IV contrast used during the scan of the pulmonary hila?
   - Was needle placement based on measurements taken from the CT scan?
   - Were accessible nodes defined as being within 1 cm or less from the tracheal wall?
   - If TBNA was performed blindly (e.g. CT or other imaging study was not performed or results of CT or other imaging study were negative for lymphadenopathy), were TBNA’s performed (at a minimum) at the side of the tracheal carina AND/OR regional mediastinum corresponding to the primary tumor?

6. Were TBNA samples collected for BOTH cytological and histological review?

A2. **Index test quality** – If TBNA was performed using ‘real-time’ imaging (e.g. CT Fluoroscopy, enbronchial ultrasound or transthoracic ultrasound):

- Was the imaging device and procedure used to locate lymph nodes clearly described in detail?
- Was an image obtained to confirm needle position prior to aspiration/biopsy?
- Were accessible nodes defined as being within 1 cm or less from the tracheal wall?

B. **Reference test quality (by study)**

1. Were both positive and negative TBNA staging results compared to a gold standard (a surgical staging procedure with lymph node evaluation/dissection and biopsy/surgical pathologic review)?

2. Was the confirmatory surgical staging procedure clearly described?

C. **Application of reference test (by study)**

1. Did all patients with a NEGATIVE TBNA undergo a surgical staging procedure with biopsy (e.g. cervical or parasternal mediastinal exploration AND/OR mediastinal exploration at thoracotomy)?
2. Did all patients with a NEGATIVE TBNA undergo a thoracotomy with systematic sampling of normal and abnormal lymph nodes at all accessible lymph node stations?

D. Independence of test interpretation
1. Was the pathologist blinded to the histologic diagnosis (either prior to TBNA or after confirmatory surgical staging procedure) before the cytology from the TBNA was reviewed?
2. If patients underwent surgical confirmation of mediastinal lymphadenopathy, was the surgeon blinded to the results of the TBNA?
3. If a CT was performed prior to TBNA, was the radiologist blinded to the patient’s clinical status?

E. Clinical description & characteristics
1. Did the study include complete demographic information as per the following:
   - Age of patients enrolled (either overall or per individual subject) was noted?
   - Sex of patients enrolled (either overall or per individual subject) was noted?
2. Was the individual subject used as the unit of analysis (e.g. not aspiration samples)?
3. Were inclusion and exclusion criteria clearly specified?

E. Cohort assembly
1. Were subjects enrolled prospectively?
2. Were subjects enrolled consecutively?
3. Was the relevant cohort assembled as per the following:
   - Did all enrolled patients have a pathologic diagnosis of NSCLC?
   - Were patients with evidence of nonresectability EXCLUDED (e.g. evidence of metastatic disease, malignant pleural effusions, etc.)?
   - Were patients at risk for a false positive result EXCLUDED (e.g. evidence of tumor within 2 cm of the carina)?
4. Was there NO evidence of workup bias (e.g. were only patients with a positive TBNA enrolled)?
5. Were patients with previous lymph node biopsy attempts excluded (e.g. negative TBNAs or other biopsy procedure prior to study)?
6. Was this a multi-center trial?

F. Sample size
1. Did at least 35 participants with NSCLC have mediastinal lymph node involvement?
2. Did at least 35 participants with NSCLC have NO mediastinal lymph node involvement?
Figure S3.

Study, Year

Studies with Prevalence < 60%
- Harrow 2000
- Disdier 1998
- Ratto 1988
- Schenk 1986
- Wang, K. P. 1983†
- Overall

Studies with Prevalence >= 60%
- Herth 2002 ‡
- Patelli 2002 †
- Wang, R. 2002 *
- Katis 1998 †
- Rong 1998 ‡
- Bilaceroglu 1998
- Schenk 1993 †
- Schenk 1989 †
- Overall ‡
Figure S4.

Log odds ratio versus standard error